Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sankyo prepares and tests new ACAT inhibitors

Nov. 4, 2002

FDA issues approvable letter for Hectorol Capsules sNDA

Oct. 31, 2002

Safety and efficacy of oral ibandronate in breast cancer-related bone events

Oct. 31, 2002

Sankyo describes new antiangiogenic agents with utility in diabetic retinopathy

Oct. 31, 2002

Further development of LY-333531 for diabetic neuropathy and vasculopathy warranted

Oct. 30, 2002

Two Genzyme enzyme replacement therapies up for FDA panel review in January

Oct. 30, 2002

First of three pivotal phase III trials of AC-2993 in type 2 diabetes completes enrollment

Oct. 30, 2002

Banyu describes novel compounds able to increase GLP-1 levels

Oct. 30, 2002

New DPP-IV inhibitors in early development at Boehringer Ingelheim

Oct. 30, 2002

Sustained activity demonstrated for Albugranin in two animal species

Oct. 29, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...